

NEWS

Contact:
Gualberto Ruaño, MD, PhD
President
Genomas, Inc.
860-545-3773



FOR IMMEDIATE RELEASE
October 18, 2006

THE HOSPITAL OF CENTRAL CONNECTICUT AND GENOMAS ESTABLISH STRATEGIC PARTNERSHIP IN DNA-GUIDED MANAGEMENT OF DIABETES

Hartford, CT – The Hospital of Central Connecticut and Genomas Inc. announced today a new partnership for Personalized and DNA-guided management of diabetes. The agreement was announced at the Hospital by Genomas President, Gualberto Ruaño, M.D., Ph.D., and by the Hospital's Senior Vice President of Medical Affairs and Chief Medical Officer Steven D. Hanks, M.D.

The hospital and Genomas have identified specific areas of engagement which include development of new DNA-guided systems for optimal selection of diabetes drugs, diet and exercise for counseling and life-style modification and development of disease management tools for advanced diabetes (including nephropathy, neuropathy and vascular disease).

In January 1997, the Hospital, then known as New Britain General Hospital, joined with the Joslin Diabetes Center in Boston, Massachusetts, a world leader in diabetes treatment, research and education. As a Joslin affiliate, the Hospital strives to meet the high standards of care for people with diabetes, and to help people with diabetes develop skills to manage their blood glucose, avoid complications and to maintain better health throughout their lifetime.

Genomas and the Hospital of Central Connecticut will jointly develop DNA-guided medical management systems for diabetes. These DNA systems predict the risk of developing liver injury, weight gain, and other adverse metabolic reactions to diabetes drugs. "The partnership with the hospital allows us to bring DNA-guided medicine to patients with diabetes. It is essential work, because the medications for which we are developing personalized prescription systems are being used more often, and at higher doses," said Gualberto Ruaño, President of Genomas.

In June 2004, Genomas forged a partnership in DNA-guided medicine with Hartford Hospital, where it is located. This partnership has already advanced DNA typing to clinical use in psychiatry and cardiology. Genomas medical management systems are currently available or under development to enhance the safety of psychiatric drugs (antidepressants, antipsychotics) and cardiovascular drugs (warfarin, statins). Genomas operates one of the country's pioneering high-complexity DNA typing laboratories for drug safety, licensed by the CT Dept. of Public Health and certified by the Centers for Medicare and Medicaid. DNA diagnostics are distributed through Clinical Laboratory Partners.

"We are excited about beginning this new chapter for the care of people with diabetes through the Genomas partnership", said Laurence A. Tanner, president and CEO of the Hospital of

Central Connecticut. “This relationship once again brings us together with Hartford Hospital as a fellow partner, highlighting both hospitals’ commitment to improve the care we deliver to our community through innovative and groundbreaking research.”

“The Hartford Hospital-Genomas partnership has yielded significant gains in DNA-guided drug prescription to prevent and diagnose adverse drug reactions,” said John Meehan, President and CEO of Hartford Hospital. “We are pleased to have the Hospital of Central Connecticut as part of the alliance, continuing decades of cooperation between our institutions.”

“We are energized by the confidence placed in us by both the Hospital of Central Connecticut and Hartford Hospital as we advance the practice of DNA-guided medicine,” said Dr. Ruaño. “Our hospital partners are pivotal anchors for the new personalized health industry we are developing in Connecticut.”

ABOUT THE HOSPITAL OF CENTRAL CONNECTICUT

The Hospital of Central Connecticut was formed Oct. 1 by the merger of New Britain General and Bradley Memorial Hospitals. With campuses in New Britain and Southington, it is a 414-bed, 32-bassinets acute-care teaching hospital affiliated with the University of Connecticut School of Medicine. The Hospital of Central Connecticut provides comprehensive inpatient and outpatient healthcare services in medicine, surgery, and a wide variety of specialties. For more information please access www.thocc.org

ABOUT GENOMAS

Genomas® Inc. is a biomedical company advancing DNA-guided medicine and personalized health. The company develops revolutionary PhyzioType™ systems for DNA-guided diagnosis and treatment of metabolic disorders induced by drugs and by diabetes in cardiovascular and psychiatric medicine. PhyzioType™ systems provide physicians with the unprecedented capability to select for each patient the safest drug treatment and the most effective disease prevention. Genomas is located in Hartford, CT on the campus of Hartford Hospital. For more information please access www.genomas.net

###